Thymosin α-1
Also known as Thymalfasin · Tα-1
A 28-amino-acid peptide produced by the thymus that modulates T-cell balance and NK-cell activity — used clinically in 30+ countries.
Definition
The peptide is produced by thymic epithelial cells and tunes the balance between T-helper-1 and T-helper-2 responses and increases natural-killer-cell activity. It holds licensure in over 30 countries as an immune adjuvant for chronic hepatitis B, oncology, and post-viral recovery. Availability in the US is through compounded prescription only.
How Meto uses it.
Meto prescribes Thymosin α-1 solo for members with chronic low-grade infection, post-viral fatigue, low NK-cell activity on labs, or seasonal immune needs. Standard dosing is subcutaneous at 1.6 mg twice weekly, typical cycle 8–12 weeks with a lab re-check at completion.
Safety notes
- Use caution in active autoimmune flare — clinician review required
- Not for use alongside immunosuppressive therapy without oncology consult
- Avoid in pregnancy and lactation
- Very well-tolerated overall — rare injection-site redness
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
Is Thymosin α-1 right for autoimmunity?
Effectiveness depends on condition and current labs. The peptide modulates rather than blocks Th1/Th2 balance; clinician review of full history, medications, and labs is required.
Will it help with long COVID?
Growing evidence exists from case-series and small trials suggesting benefit in post-viral fatigue, though it's not an established cure—rather, a reasonable part of a multi-modal recovery plan.
Why is it less-known in the US?
The US route via compounded prescription represents a regulatory artefact rather than a safety signal.
Read More
Compounded Peptide
A peptide prepared for an individual patient by a licensed compounding pharmacy, prescribed by a clinician and tested for identity, potency and contamination.
PeptideThymosin β-4Tβ4
The parent peptide behind TB-500 — a 44-amino-acid naturally occurring actin-regulating peptide studied for systemic repair.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.